Serum miR-375 for Diagnostic and Prognostic Purposes in Medullary Thyroid Carcinoma.

Front Endocrinol (Lausanne) · 2021 · PMC8039521 · PMID 33854485

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP = 0.05actually significant

A trend towards higher median miR-375 levels was seen in patients with lower tumor stages at diagnosis (19.28, IQR: 9.79–37.4 for patients in stages I+II vs 7.45, IQR: 3.12–29.73 for those in stages III+IV), although the difference did not reach statistical significance (P = 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.